Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Anonymous multiple to fund legal challenge against cuts

An unnamed multiple has agreed to fund the costs of a legal challenge against the pharmacy funding cuts, C+D has learned.

David Reissner, senior healthcare partner at law firm Charles Russell Speechlys, confirmed to C+D today (November 1) that a client has asked him to “obtain a [senior lawyer’s] opinion on the lawfulness of the cuts” to pharmacy funding in England.

“I’ll be doing that as quickly as possible,” he told C+D.

Mr Reissner said he could not name the business in question, but confirmed “it is a multiple”.

The law firm urged pharmacists to contribute to the cost of a legal challenge last week (October 26), saying that just £10 from every pharmacy would help raise the “low six-figure sum” needed to fund the cost of a senior lawyer taking the “urgent hearings” to court.

Noel Wardle, a partner at the firm, said it had received “quite a flurry of contacts from pharmacists saying they’ll contribute” after the call-out.

Would you contribute to legally challenging the cuts?

Related Content


Lead Pharmacist
£30 per hour

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts